QL1706 (bispecific antibody targeting PD-1 and CLTA-4) Clinical Trials
5 recruitingDrug
Phase 24Phase 12
Showing 1–5 of 5 trials
Recruiting
Phase 2
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Consolidation ImmunotherapyChemoradiotherapyLimited-stage Small Cell Lung Cancer (LS-SCLC)+1 more
Shanghai Chest Hospital28 enrolled1 locationNCT07091305
Recruiting
Phase 1
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
TNBC - Triple-Negative Breast Cancer
Xijing Hospital30 enrolled1 locationNCT07178171
Recruiting
Phase 2
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Bone and Soft Tissue Tumors
Sun Yat-sen University45 enrolled1 locationNCT06939855
Recruiting
Phase 2
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Fudan University56 enrolled1 locationNCT07070700
Recruiting
Phase 1Phase 2
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Solid TumorsLeptomeningeal MetastasisCTLA4+2 more
Guangzhou Medical University34 enrolled2 locationsNCT06809530